Literature DB >> 33762682

PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.

Jeffrey M Cloutier1, Grace Allard1, Gregory R Bean1, Jason L Hornick2, Gregory W Charville3.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a spindle cell neoplasm of the skin and superficial soft tissue with a tendency for locally aggressive behavior; metastatic potential coincides with fibrosarcomatous transformation. The vast majority of DFSPs harbor the t(17;22) translocation resulting in a COL1A1-PDGFB fusion that drives autocrine growth stimulation via PDGFB overexpression. Here, we examined the utility of PDGFB RNA chromogenic in situ hybridization (CISH) for the diagnosis of DFSP. A total of 337 tumors represented in whole tissue sections and tissue microarrays, including 37 cases of DFSP and 300 histologically similar spindle cell tumors, were subjected to PDGFB RNA CISH using commercially available probes. PDGFB overexpression was observed by light microscopy in 24 of 26 conventional DFSPs (92%) and 11 of 11 fibrosarcomatous DFSPs (100%). One of two DFSPs negative for PDGFB by RNA CISH was found to harbor an uncommon alternative rearrangement involving PDGFD. All examined cases of histologic mimics were negative for PDGFB overexpression; limited PDGFB expression, not reaching an empirical threshold of greater than 5 puncta or one aggregate of chromogen in more than 25% of cells, was observed in 7 of 300 mimics (2.3%), including desmoplastic melanoma, malignant peripheral nerve sheath tumor, angiosarcoma, and pleomorphic dermal sarcoma. Vascular PDGFB expression was seen in several tumor types. We conclude that PDGFB RNA CISH, with careful interpretation and the use of appropriate thresholds, may serve as a surrogate marker of PDGFB rearrangement and a useful ancillary tool for the diagnosis of DFSP.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33762682      PMCID: PMC8298273          DOI: 10.1038/s41379-021-00800-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  29 in total

1.  Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: clinicopathologic analysis of 5 cases.

Authors:  E Calonje; C D Fletcher
Journal:  J Cutan Pathol       Date:  1996-02       Impact factor: 1.587

2.  Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy.

Authors:  David I Suster; Pawel Kurzawa; Azfar Neyaz; Jason A Jarzembowski; Santiago Lozano-Calderon; Kevin Raskin; Joseph Schwab; Edwin Choy; Ivan Chebib; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2020-12       Impact factor: 6.394

3.  Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Authors:  Jared J Abbott; Michele Erickson-Johnson; Xiaoke Wang; Antonio G Nascimento; Andre M Oliveira
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

Review 4.  Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.

Authors:  Nicolas Sirvent; Georges Maire; Florence Pedeutour
Journal:  Genes Chromosomes Cancer       Date:  2003-05       Impact factor: 5.006

5.  CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.

Authors:  P Abenoza; T Lillemoe
Journal:  Am J Dermatopathol       Date:  1993-10       Impact factor: 1.533

6.  Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.

Authors:  Julie D R Reimann; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-09       Impact factor: 6.394

7.  Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.

Authors:  Leona A Doyle; Marina Vivero; Christopher Dm Fletcher; Fredrik Mertens; Jason L Hornick
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

8.  STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors.

Authors:  Akihiko Yoshida; Koji Tsuta; Makoto Ohno; Masayuki Yoshida; Yoshitaka Narita; Akira Kawai; Hisao Asamura; Ryoji Kushima
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

9.  STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics.

Authors:  Alison L Cheah; Steven D Billings; John R Goldblum; Paula Carver; Munir Z Tanas; Brian P Rubin
Journal:  Pathology       Date:  2014-08       Impact factor: 5.306

10.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  2 in total

Review 1.  Diagnosis of soft tissue tumors using immunohistochemistry as a surrogate for recurrent fusion oncoproteins.

Authors:  Margaret A Black; Gregory W Charville
Journal:  Semin Diagn Pathol       Date:  2021-11-03       Impact factor: 3.464

2.  Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.

Authors:  Katharina Röltgen; Sandra C A Nielsen; Oscar Silva; Sheren F Younes; Maxim Zaslavsky; Cristina Costales; Fan Yang; Oliver F Wirz; Daniel Solis; Ramona A Hoh; Aihui Wang; Prabhu S Arunachalam; Deana Colburg; Shuchun Zhao; Emily Haraguchi; Alexandra S Lee; Mihir M Shah; Monali Manohar; Iris Chang; Fei Gao; Vamsee Mallajosyula; Chunfeng Li; James Liu; Massa J Shoura; Sayantani B Sindher; Ella Parsons; Naranjargal J Dashdorj; Naranbaatar D Dashdorj; Robert Monroe; Geidy E Serrano; Thomas G Beach; R Sharon Chinthrajah; Gregory W Charville; James L Wilbur; Jacob N Wohlstadter; Mark M Davis; Bali Pulendran; Megan L Troxell; George B Sigal; Yasodha Natkunam; Benjamin A Pinsky; Kari C Nadeau; Scott D Boyd
Journal:  Cell       Date:  2022-01-25       Impact factor: 66.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.